% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Verger:1041313,
author = {Verger, Antoine and Tolboom, Nelleke and Cicone, Francesco
and Chang, Susan M. and Furtner, Julia and Galldiks, Norbert
and Gempt, Jens and Guedj, Eric and Huang, Raymond Y. and
Johnson, Derek R. and Law, Ian and Le Rhun, Emilie and
Short, Susan C. and Bent, M. J. Van den and Weehaeghe,
Donatienne Van and Vogelbaum, Michael A. and Wen, Patrick Y.
and Albert, Nathalie L. and Preusser, Matthias},
title = {{J}oint {EANM}/{EANO}/{RANO}/{SNMMI} practice
guideline/procedure standard for {PET} imaging of brain
metastases: version 1.0},
journal = {European journal of nuclear medicine and molecular imaging},
volume = {52},
number = {5},
issn = {1619-7070},
address = {Heidelberg [u.a.]},
publisher = {Springer-Verl.},
reportid = {FZJ-2025-02212},
pages = {1822 - 1839},
year = {2025},
abstract = {This joint practice guideline/procedure standard was
collaboratively developed by the European Association of
Nuclear Medicine (EANM), the Society of Nuclear Medicine and
Molecular Imaging (SNMMI), the European Association of
Neuro-Oncology (EANO), and the PET task force of the
Response Assessment in Neurooncology Working Group
(PET/RANO). Brain metastases are the most common malignant
central nervous system (CNS) tumors. PET imaging with
radiolabeled amino acids and to lesser extent [18F]FDG has
gained considerable importance in the assessment of brain
metastases, especially for the differential diagnosis
between recurrent metastases and treatment-related changes
which remains a limitation using conventional MRI. The aim
of this guideline is to assist nuclear medicine physicians
in recommending, performing, interpreting and reporting the
results of brain PET imaging in patients with brain
metastases. This practice guideline will define procedure
standards for the application of PET imaging in patients
with brain metastases in routine practice and clinical
trials and will help to harmonize data acquisition and
interpretation across centers.Keywords: Brain metastases;
Brain metastasis; FDG; FDOPA; FET; Fluciclovine; Metastatic
brain tumors; Methionine; PET; Recurrence.},
cin = {INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406},
pnm = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
pid = {G:(DE-HGF)POF4-5252},
typ = {PUB:(DE-HGF)16},
pubmed = {39762634},
UT = {WOS:001390889200001},
doi = {10.1007/s00259-024-07038-5},
url = {https://juser.fz-juelich.de/record/1041313},
}